Emerging Therapies for Rheumatoid Arthritis - Wikidata - awgldk - TriplyDB

Emerging Therapies for Rheumatoid Arthritis

Emerging Therapies for Rheumatoid Arthritis

http://www.wikidata.org/entity/Q28078943

about

Update of sarilumb to treat rheumatoid arthritis based on randomized clinical trials: a systematic review.Sirukumab: a promising therapy for rheumatoid arthritis.Factors associated with the risk of gingival disease in patients with rheumatoid arthritis.European perspective on the management of rheumatoid arthritis: clinical utility of tofacitinib.Clinical characteristics and patient-reported outcomes in patients with inadequately controlled rheumatoid arthritis despite ongoing treatment.Fabrication of a triptolide-loaded and poly-γ-glutamic acid-based amphiphilic nanoparticle for the treatment of rheumatoid arthritis.

P2860

Q38660813-81E3DC8B-EA6C-416C-80CC-B1C3BA07A10E Q38856800-A56BF850-3B4E-4ECD-A674-68BD7973883C Q42375845-C0416B39-2C83-4B3B-AE0E-F14505E7720B Q47338654-091B7916-EA2C-40C7-AEA3-3B9A339B2A90 Q52624368-7FD616EF-E5EC-4B0E-A909-BC424828D324 Q55514601-53CD0C65-5652-43BA-AF49-E3A6F248BB02

P2860

Emerging Therapies for Rheumatoid Arthritis

http://www.wikidata.org/entity/Q28078943

description

2016 nî lūn-bûn

@nan

2016 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Emerging Therapies for Rheumatoid Arthritis

@ast

Emerging Therapies for Rheumatoid Arthritis

@en

Emerging Therapies for Rheumatoid Arthritis

@nl

type

label

Emerging Therapies for Rheumatoid Arthritis

@ast

Emerging Therapies for Rheumatoid Arthritis

@en

Emerging Therapies for Rheumatoid Arthritis

@nl

prefLabel

Emerging Therapies for Rheumatoid Arthritis

@ast

Emerging Therapies for Rheumatoid Arthritis

@en

Emerging Therapies for Rheumatoid Arthritis

@nl

P1433

Q28078943-45D932B3-0ECE-4562-AE42-98D6EA62BB4C

P1476

Q28078943-A30C87F5-E2A8-4F76-AD71-C839BB436583

P2093

Q28078943-E61A602A-74E7-4073-97CD-A0C48EEB5DED

P2860

Q28078943-04C8A1BB-DE09-47DC-A06E-4C135C777FF2

Q28078943-04E3EB1C-C932-48EE-A166-E37B7BF48D10

Q28078943-061F6AA6-10F3-4962-9407-7F65E9D84123

Q28078943-09F26E3E-F087-42E2-A0C3-E22D9BDB27F0

Q28078943-10724CA4-4C4D-42C4-A47B-CE10699EF39B

Q28078943-10F14EF5-FA65-4E7A-ADE2-13E23214D99C

Q28078943-11023D0F-330A-4209-8494-077D3168D09D

Q28078943-1946A932-E949-432C-B5FA-A4EA8F59D4D0

Q28078943-1B23BCAC-68A1-4E2F-8474-0362CC0D4720

Q28078943-1D62C8BF-BF5B-455E-9900-CC8BC3A6A80D

P2888

Q28078943-78B51B4E-6C8B-4AB7-BEF4-17EC320F4665

P304

Q28078943-006A1194-BF9A-44B8-BA44-4398AA3C5E49

P31

Q28078943-2B985B86-C5FF-47F5-8E7D-0AA06EB0E8AE

P3181

Q28078943-24D814DD-463E-4B05-AB78-4F7E05EA12D8

P356

Q28078943-EAF1A10C-E0AF-43BE-9834-7F8F816B0ADF

P407

Q28078943-66DD9B39-28B0-4687-B048-DA169E7FDECC

P433

Q28078943-9FC6F5DB-1ED6-479B-8E85-B80B9ACC7FC4

P478

Q28078943-D057BB98-7F0A-4751-B69D-A8621EB73D6D

P577

Q28078943-416FE9B3-FD50-431E-A115-B3B6A13F7022

P6179

Q28078943-D86E2D09-2C60-4E84-952A-2BBEAC38C67E

P698

Q28078943-D6961139-4A3C-462F-9677-7E7E97721483

P932

Q28078943-082B36D9-92F4-4FD8-BE33-101B54404354

P3181

P356

S40744-016-0032-4

P1433

Rheumatology and therapy

P1476

Emerging Therapies for Rheumatoid Arthritis

@en

P2093

Joachim. R. Kalden

http://www.w3.org/2001/XMLSchema#string

P2860

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases

Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412

Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases.

Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies.

New insights into the regulation of T cells by gamma(c) family cytokines

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.

Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study.

Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy.

The role of interleukin-2 during homeostasis and activation of the immune system.

P2888

s40744-016-0032-4

P304

31-42

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1516745

http://www.w3.org/2001/XMLSchema#string

P356

10.1007/S40744-016-0032-4

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2016-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1033655391

http://www.w3.org/2001/XMLSchema#string

P698

27747522

http://www.w3.org/2001/XMLSchema#string

P932

4999582

http://www.w3.org/2001/XMLSchema#string